Jose M Sanchez-Tapias

Summary

Country: Spain

Publications

  1. ncbi request reprint Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
    Jose M Sanchez-Tapias
    Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Gastroenterology 131:451-60. 2006
  2. ncbi request reprint [Pharmacological agents for the treatment of chronic hepatitis B]
    Jose M Sanchez-Tapias
    Servicio de Hepatologia, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Gastroenterol Hepatol 31:120-8. 2008
  3. ncbi request reprint Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C
    Eva Martinez-Bauer
    Liver Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Hepatology 43:72-80. 2006
  4. ncbi request reprint Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C
    Francesc Puig-Basagoiti
    Liver Unit, Institut de Malalties Digestives, Departament de Medicina IMD, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Spain
    J Gen Virol 86:1067-75. 2005
  5. ncbi request reprint Hepatitis C: who should you treat and how?
    Jose M Sanchez Tapias
    Liver Unit, Hospital Clinic, University of Barcelona, Spain
    Blood Purif 20:124-36. 2002
  6. doi request reprint Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients
    Montserrat Laguno
    Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
    Hepatology 49:22-31. 2009
  7. ncbi request reprint Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases
    Manuel Ramos-Casals
    Department of Autoimmune Diseases, School of Medicine, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, Barcelona, Spain
    Semin Arthritis Rheum 36:189-96. 2006
  8. ncbi request reprint Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients
    Jose M Sanchez-Tapias
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, University of Barcelona, IDIBAPS, Spain
    Gastroenterology 123:1848-56. 2002

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
    Jose M Sanchez-Tapias
    Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Gastroenterology 131:451-60. 2006
    ..This study investigated whether treatment for 72 weeks increases the rate of SVR in patients with detectable hepatitis C virus (HCV)-RNA levels at week 4 of treatment...
  2. ncbi request reprint [Pharmacological agents for the treatment of chronic hepatitis B]
    Jose M Sanchez-Tapias
    Servicio de Hepatologia, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Gastroenterol Hepatol 31:120-8. 2008
  3. ncbi request reprint Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C
    Eva Martinez-Bauer
    Liver Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Hepatology 43:72-80. 2006
    ..In conclusion, these models predicted response to therapy before or after 4 weeks of treatment in approximately 60% of genotype 1 patients and may be valuable for the management of this condition...
  4. ncbi request reprint Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C
    Francesc Puig-Basagoiti
    Liver Unit, Institut de Malalties Digestives, Departament de Medicina IMD, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Spain
    J Gen Virol 86:1067-75. 2005
    ..These observations suggest that the composition and dynamics of HCV NS5A quasispecies, particularly in the V3 domain, may play a role in the response to combined IFN/ribavirin therapy...
  5. ncbi request reprint Hepatitis C: who should you treat and how?
    Jose M Sanchez Tapias
    Liver Unit, Hospital Clinic, University of Barcelona, Spain
    Blood Purif 20:124-36. 2002
    ....
  6. doi request reprint Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients
    Montserrat Laguno
    Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
    Hepatology 49:22-31. 2009
    ..47). Conclusion: In patients with HIV, HCV therapy with PEG 2b or PEG 2a plus RBV had no significant differences in efficacy and safety...
  7. ncbi request reprint Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases
    Manuel Ramos-Casals
    Department of Autoimmune Diseases, School of Medicine, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, Barcelona, Spain
    Semin Arthritis Rheum 36:189-96. 2006
    ..To analyze the etiology, clinical presentation, and outcomes of patients with life-threatening cryoglobulinemic vasculitis...
  8. ncbi request reprint Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients
    Jose M Sanchez-Tapias
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, University of Barcelona, IDIBAPS, Spain
    Gastroenterology 123:1848-56. 2002
    ..The aim of this study was to investigate if the variable outcome of chronic hepatitis B may be related to hepatitis B virus (HBV) genotype...